Salute e Benessere
EnChannel Medical to Acquire Acutus Medical AcQMap™ Electrophysiology Assets
Conventional contact mapping systems sequentially collect electrical signals by making physical contact with many small regions of cardiac tissue, generating regional maps of electrical activity over numerous beats that are gradually assembled into a composite view across the chamber surface. While effective for regular rhythms, it is time-consuming, and it cannot capture the full dynamics of irregular activation patterns, such as in AF, often averaging out critical details and reducing mapping accuracy and specificity.
In contrast, non-contact mapping (NCM) reconstructs full-chamber electrical activity from cardiac signals sensed by numerous electrodes distributed within the atrial chamber cavity. NCM delivers a comprehensive, single-beat depiction of activation over the entire atrial chamber at every instance of time. This approach significantly improves mapping efficiency and preserves the dynamic patterns of both regular and complex, irregular rhythms, including AF.
Acutus' AcQMap™ technology is a second-generation NCM platform that advanced beyond the first-generation voltage-to-voltage mapping (pioneered by Endocardial Solutions – now part of Abbott), and delivered improved spatial resolution and accuracy, using voltage-to-charge-density mapping.
EnChannel's propriety Action Potential Mapping offers a third-generation breakthrough in NCM technology, with accurate reconstruction of both depolarization and repolarization dynamics. This fulfills a biophysical unmet need that remains in conventional mapping, which cannot address repolarization. Action Potential Mapping therefore approaches the real nature of cardiac conduction and enables comprehensive understanding of the mechanisms that initiate and maintain AF – laying the groundwork for precise, individualized treatment of persistent AF.
Founded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China , EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions.
For more information, visit http://www.enchannel.com and follow us on LinkedIn.
EnChannel's mapping and ablation products are investigational devices and are limited by federal (or United States) law to investigational use.
Bradley Wegrzynowicz
(610) 462-0197
Bradley.wegrzynowicz@enchannel.com
Logo - https://mma.prnewswire.com/media/2677615/EnChannel_Logo.jpg
Photo - https://mma.prnewswire.com/media/2722428/Electrophysiological_Source_Pyramid_Infographic.jpg
View original content:https://www.prnewswire.co.uk/news-releases/enchannel-medical-to-acquire-acutus-medical-acqmap-electrophysiology-assets-302495131.html